Connect Biopharmaceuticals Advances CBP-201, a Novel Monoclonal Antibody Against IL-4Ra, Into Clinical Development

Tuesday, April 24, 2018 Drug News
Email Print This Page Comment bookmark
Font : A-A+

TAICANG, China, April 24, 2018 /PRNewswire/ -- Connect Biopharmaceuticals, Ltd. today announced that it has submitted an

application in Australia to begin a phase 1 clinical trial to evaluate CBP-201, the company's monoclonal antibody candidate for allergic inflammation.

The planned phase 1 clinical trial is a randomized, double-blind,

placebo-controlled study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of CBP-201. At least 40 healthy subjects will be enrolled in this single ascending dose study.

"We are very excited to begin the process of initiating our first-in-man study of CBP-201, a novel and highly potent monoclonal antibody against interleukin-4 receptor alpha (IL-4R?).  IL-4R? is a clinically-validated target known to mediate the biological activities of both IL-4 and IL-13, two key cytokines driving a broad array of allergic inflammatory diseases," said Jeffery White, MD, Chief Medical Officer of Connect Biopharmaceuticals. "Preclinical studies showed that CBP-201 had superior potency and pharmacokinetic properties compared to existing IL-4R? antibodies currently in clinical development. Using well-validated biomarkers, we expect this phase 1 study to provide important safety, PK, and PD data with CBP-201 to support further clinical development in patients."

"We are extremely pleased that Connect has once again advanced a high-quality, internally-discovered drug candidate into clinical studies," said Dr. Zheng Wei, CEO of Connect. "The progress of CBP-201 further validated our efficient operational strategy, which combines our strong expertise in T-cell modulation with efficient collaborations with top-quality CROs to deliver new therapeutics for inflammatory diseases with high unmet need both in China and globally."

About Connect Biopharmaceuticals

Connect Biopharmaceuticals is a China-based global clinical-stage company focused on discovery and development of novel immune modulators for the treatment of autoimmune diseases and inflammation. Our drug discovery technology platform is built on the biology of T cell functions, which identifies molecules that target clinically-validated disease pathways.

Our lead drug candidate is CBP-307, an orally-active, next-generation S1P1 and S1P5 (a G-protein coupled receptor -GPCR) modulator for the treatment of a range of autoimmune disorders, including inflammatory bowel disease, psoriasis, multiple sclerosis and other autoimmune diseases.  We have completed a phase 1b randomized, double-blind, placebo-controlled study that assessed the safety, tolerability, pharmacokinetics, and pharmacodynamics of CBP-307. In this study, CBP-307 exhibited an excellent safety profile and potent T cell modulation activity as well as optimal pharmacokinetic and pharmacodynamic profiles, demonstrating best-in-class potential. CBP-307 is entering phase 2 studies of ulcerative colitis and Crohn's disease.

Our second drug candidate is CBP-201, a novel monoclonal antibody that targets IL-4R? and blocks a central pathway in allergic inflammation, and will be studied for the treatment of atopic dermatitis, asthma, and other inflammatory conditions. Additional programs included CBP-174, CBP-233, and CBP-312.

Media Contact:

Rosemary Chang

Tel: +86-512-53577866

qchang@connectpharm.com

 

Cision View original content:http://www.prnewswire.com/news-releases/connect-biopharmaceuticals-advances-cbp-201-a-novel-monoclonal-antibody-against-il-4r-into-clinical-development-300635095.html

SOURCE Connect Biopharmaceuticals, Ltd.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store